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Abstract
Many people are diagnosed with thyroid related disorders, and many more are
unaware of their existing thyroid problems. T1AM, a naturally occurring metabolite of the
thyroid hormone (TH), has been shown to activate the Trace Amine Associated Receptor
1 (TAAR1) and exhibits effects that oppose those of the TH. It is, therefore, likely that
there is regulatory relationship between T1AM and the TH. In order to better understand
this relationship, a compound must be developed that will effectively block TAAR1.
Previously our lab has examined the two different mirror images of apomorphine. One of
the mirror images inhibited and the other activated TAAR1. The project described herein,
is targeted toward the synthesis of a truncated ergoline, which is structurally similar to
both T1AM and apomorphine. Only one mirror image is present in the naturally occurring
form of ergolines, and they are known to be activators of TAAR1. To determine if the
non-natural mirror image is an effective inhibitor, it is essential that an efficient synthesis
be developed that will allow for the formation of both mirror images of the truncated
ergoline. Several steps have been optimized using the desired system, and several other
steps have been optimized using a model system. Currently the key step for the
completion of the truncated ergoline is being examined using data collected from the
model system.
Introduction
Many people each year are diagnosed with thyroid hormone (TH) related
disorders, and there are many more who are unaware of their existing condition. The
current treatment options are very limited, and provide a non-comprehensive approach to
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treating such disorders. Further research into the biochemical regulatory processes of the
TH production and post-thyroid metabolism may be the key to unlocking more
comprehensive treatment options. This project is targeted toward synthesizing a molecule
that will help us to better understand this regulatory process.
Figure 1
Structural Comparison of TH and T1AM
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In the body there are two chemical compounds normally associated with the
thyroid hormone: Thyroxine (T4) and triiodothyronine (T3). T4 is the most prevalent
form of the thyroid hormone in the body, while T3 is the most potent form. T4 acts as a
non-potent reservoir of the TH that is converted via enzymes in the liver, kidney, and
other tissues to the more potent T3. Hyperthyroidism and Hypothyroidism are the two
most common disorders associated with the thyroid. Classically hyperthyroidism was
associated with too much TH in the body and was characterized by symptoms including
increased core body temp, metabolism, and heart rate (tachycardia). Similarly,
hyperthyroidism was classically associated with too little TH in the body and was
characterized by symptoms including decreased core body temp, metabolism, and heart
rate (bradycardia).
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Recently the discovery of a natural metabolite of the TH, 3-iodothyronamine
(T1AM), has begun to shed some light on a possible biochemical regulatory process of
the TH[1]. In rats and mice, T1AM exhibited physiological effects opposite those
associated with the TH. An increase in T1AM levels caused bradycardia with a decrease
in core body temp and metabolism. Due to the fact that T1AM is a natural metabolite of
the TH, it has been proposed that it might be a negative regulator of the TH. If this is the
case, then the symptoms normally associated with hyperthyroidism may not only be
caused by too much TH, but also caused by too little T1AM. Also, the symptoms
normally associated with hypothyroidism, may not only be caused by too little TH, but
also caused by too much T1AM. The symptoms may arise due to an imbalance in these
compounds (figure 2). If this is the case, then targeting this imbalance may lead to new
treatments for people suffering from hyperthyroidism and hypothyroidism.
Figure 2
Hypothyroidism vs. Hyperthyroidism

In order to prove this relationship exists, we need to better understand the
regulation of the receptor for T1AM. This receptor is a G-Protein Coupled Receptor
(GPCR) called Trace Amine Associated Receptor 1 (TAAR1). Many agonists (activators)
of this receptor, like T1AM, have been tested, but there are very few successful
antagonists (inhibitors) of this receptor. Several compounds have been reported; however,
these exhibit only modest inhibition at best.
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Figure 3
R- and S-Apomorphine
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Upon the discovery of TAAR 1, the two mirror images of a compound called
apomorphine were separated and tested independently[2]. It was noted that the R(-)apomorphine was an activator while S(+)-apomorphine was not. S(+)-apomorphine,
however, was not tested as an inhibitor in this study. Apomorphine is an example of an
enantiomer, which is the name given to two compounds with the same bond-to-bond
structure but with different special arrangement. The two compounds are nonsuperimposable mirror images of each other. The Hart lab decided to test S(+)apomorphine to see if it was an inhibitor, and it was experimentally determined to be the
best inhibitor reported thus far. The amount of compound needed to block half of the
receptor (the IC50 value) was 835nM. This is the first inhibitor for TAAR1 in the nM
range. Using T1AM as a reference for comparison, the amount of compounded needed to
activate half of the receptor (EC50 value) is 24nM. It is intriguing to consider
enantiomers with different activity profiles. The focus of this research is to explore this
concept in other groups of stereoisomers.
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Figure 4
Structural Comparison
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Ergolines were also tested upon the discovery of TAAR1, and they were found to
be good activators[2]. Only one stereoisomer of the ergolines occurs in nature, so in order
to test the other non-naturally occurring stereoisomer, it must be synthesized. The
truncated ergoline is the simplest form of the ergoline structure, and it incorporates a
phenethylamine (highlighted in red) that is found in both apomorphine and T1AM. It also
contains a stereocenter like apomorphine, and a secondary amine that may mimic the
iodine from T1AM. The project discussed below is focused on the synthesis of a
truncated ergoline.
Results and Discussion
The proposed synthesis in scheme 1 illustrates the current method being examined
to make the truncated ergoline, 7. The aminobromination (5), the formation of the
aziridine (6), and the intramolecular cyclization to form the truncated ergoline (7) have
not yet been tested on the target system. A styrene test system has been used to test the
aminobromination, and the aziridine formation. Data collected from these tests is being
applied to the target system.
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Scheme 1
Proposed Synthesis of Truncated Ergoline
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Scheme 2
O-Alkylation with Allyl Bromide
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Table 1
Data for O-Alkylation with Allyl Bromide
Base
K2CO3
K2CO3
Cs2CO3
Cs2CO3

Solvent
THF
Acetone
Acetone
Acetone

Temp.
Reflux
Reflux
Reflux
Room Temp

Rxn Time (Hours)
14.5-26
23
22
19

% Yield
20-27
99
58
100

The first step of the synthesis was an o-alkylation of the hydroxyl on the starting
material, 5-hydroxyindole (1). In many of the first trials this compound was refluxed,
which promoted a small amount of 2 to rearrange to 3. The claisen rearrangement is the
second step in the synthetic process, but the premature rearrangement became
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problematic due to that fact that it very difficult to separate from the unreacted starting
material. By changing the base to Cs2CO3, which is a stronger base, it allowed the
reaction to be carried out at room temperature. This allowed us to convert all of the
starting material and avoid any of the rearrangement. No separation or purification was
needed when Cs2CO3 in acetone was used.
Scheme 3
Claisen Rearrangement
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Table 2
Data for Claisen Rearrangement
Solvent
1,2,4,5-Tetramethylbenzene
M-xylene

Temp. (oC)
190-195
139

Rxn Time
3-6 hours
5 days

M-xylene (Sealed Tube)

190-195

2 days

% Yield
55-86
89
100 (with recovery
of staring material)

The second step involved the claisen rearrangement of 2. The literature source for
this claisen rearrangement called for the use of 1,2,3,4-tetramethylbenzene as the solvent,
but 1,2,4,5-tetramethylbenzene was used instead because it was more readily available
and much less expensive[3]. It is noteworthy that both 1,2,3,4-tetramethylbenzene and
1,2,4,5-tetramethylbenzene reflux between 190-195oC, but only 1,2,3,4tetramethylbenzene is a liquid at room temperature. As a result, it was very difficult to
work with the solid 1,2,4,5-tetramethylbenzene as a solvent. This required us to heat the
solvent until it was molten and then add 2 to the reaction flask. Purification of the
reaction was also quite difficult using column chromatography. The 1,2,4,5-
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tetramethylbenzene was eluted using hexane, and the product was eluted using a mixture
of hexane and ethyl acetate.
M-xylene was used as an alternative solvent because it is a liquid at room
temperature. The lower boiling point of m-xylene compared to tetramethylbenzene
caused a much longer reaction time that was impractical. It was proposed that a sealed
tube be used with the m-xylene so that the reaction temperature could be increased to a
boiling point comparable with tetramethylbenzene. The sealed tube allowed the reaction
to run in m-xylene while at a temperature of 190-195oC. This reaction was purified in the
same way that the tetramethylbenzene was purified, but recovery of unreacted starting
material was now possible. With the recovery of both the product and the small amount
of unreacted staring material, an effective yield of 100% was obtained.
Scheme 4
Aminobromination and Aziridine Formation on Styrene
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With the rearranged product in hand, we pursued the aziridination of the olefin.
Due to the high cost of the 5-hydroxyindole (1), a styrene test system (8) was used to test
the aziridine formation. The original planned synthesis was to go directly from 8 to 10
using dirhodium caprolactamate as a catalyst[4]. This catalyst also had to be synthesized,
and when tested it did not work for us[5]. Due to the high cost of rhodium chemistry, an
alternative method was used. This method involved a MnSO4 catalyst to aminobrominate
the allyl group of styrene[6]. As it turns out, 9 is a proposed intermediate that the rhodium
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catalyst uses to form the aziridine. This alternative method added an extra step, but it
provided a much cheaper alternative to the rhodium chemistry.
Table 3
Data for Aminobromination of Styrene
Rxn Time (Hours)
18.5
27

% Yield
27.8
48.2 (Not
completely pure)

The purification of 9 proved to be challenging when using hexane and ethyl
acetate. It was noted that 9 was mostly insoluble in dichloromethane (DCM), and only the
p-toluenesulfonamide shared this property. Due to this fact, DCM was added to the
reaction flask after the workup. A precipitate formed, which we determined to be pure
product. Occasionally there would be some p-toluenesulfonamide contamination. It’s
anticipated that separation of the target system will be easier.
Table 4
Data for Aziridination of Styrene
Base
K2CO3
Cs2CO3

Rxn Time (Hours)
20
20

% Yield
90.94
100

The intramolecular cyclization of the p-toluenesulfonamide in 9 to form the
aziridine on 10 was run in DCM with a base. Cs2CO3, which was the better base in the
alkylation, turned out to improve the yield of this reaction as well. The complete
conversion of 9 to 10 makes the low yield of the aminobromination more tolerable. If a
higher yield is obtained for the formation of 5 than what was obtained for 9, the aziridine
formation on the target system could be a very successful reaction.
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Scheme 5
Failed Aminobromination
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The chemistry tested on the styrene system was then implemented using 3 in
scheme 5, but the reaction did not go as planned. A black mass developed as soon as the
NBS was added to the reaction flask. It was thought that this might be due to an
intramolecular cyclization of the aminobrominated product onto the oxygen of the
hydroxyl. The indole ring system is also light sensitive, and it is also possible that
radicals could have caused some unexpected chemistry with the NBS. The first step in
trying to solve this problem was to protect the hydroxyl as an ether.
Scheme 6
O-Alkylation with Methyl Iodide
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Table 5
Data for O-Alkylation with Methyl Iodide
Rxn Time (Hours)
21

% Yield
69.5

The conversion of the hydroxyl into a methoxy group was carried out via a second
o-alkylation. This reaction has only been attempted once, so there was not time to
optimize the yield. This initial trial, however, indicates that the reaction was successful at
producing 4 even if low yielding.
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Conclusion and Future Work
Much progress has been made toward the synthesis of the truncated ergoline, but
there is still much work to be done. To date, the first alkylation and the claisen
rearrangement have been optimized for the target system. The second alkylation for the
synthesis of 4 has shown to be successful, however, optimization of this reaction has yet
to be completed. Some very valuable data was collected from the styrene test system, and
this was unsuccessfully tested on 3. It is hoped that with the protection of the hydroxyl
the aminobromination of 4 will be more successful.
On several occasions Cs2CO3 instead of K2CO3 improved yields and purity. When
using Cs2CO3 for the first alkylation, complete conversion of the starting material was
observed with no need for purification. This was also observed when using Cs2CO3 to
form the aziridine after the aminobromination. The astonishing improvement to the yield
and purity make Cs2CO3 much more favorable than K2CO3 for future reactions.
Continuing work on progress toward the synthesis of the truncated ergoline will
be done in the following semesters. If the aziridine can be obtained on the target system,
then testing will be done on the final step of this novel intramolecular cyclization of the
aziridine to form a truncated ergoline. If this can be accomplishing, we will not only have
been successful at developing the most efficient synthesis of a truncated ergoline, but also
developed a compound that will hopefully be an effective agonist for TAAR1.
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